Alpha Cognition (ACOG) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Definitive additional proxy materials filed, indicating updates or supplemental information for shareholders.
Voting matters and shareholder proposals
Shareholders are provided with options to request interim and annual financial statements and MD&A by mail or online.
Shareholder rights and capital structure
Shareholders can opt in to receive financial statements, supporting transparency and informed voting.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Alpha Cognition
- FDA-approved ZUNVEYL launches in March, targeting LTC Alzheimer's with improved tolerability.ACOG
Investor Update9 Jan 2026 - ZUNVEYL launched in US, $52.8M raised, and strong liquidity supports global expansion.ACOGQ4 202427 Dec 2025
- Biopharma seeks up to $250M to fund Alzheimer's drug launch and pipeline, with $75M ATM offering.ACOGRegistration Filing16 Dec 2025
- 2.38M shares registered for resale; ZUNVEYL launch and Asia-Pacific deal drive growth.ACOGRegistration Filing16 Dec 2025
- ZUNVEYL's launch and Asia-Pacific licensing drive growth amid ongoing net losses and Nasdaq listing.ACOGRegistration Filing16 Dec 2025
- ZUNVEYL targets major growth in 2026 with new data, expanded access, and global milestones.ACOGFireside Chat3 Dec 2025
- Key votes on board, auditor, and new equity plan highlight governance and compensation focus.ACOGProxy Filing2 Dec 2025
- AGM to vote on directors, auditors, and 2025 stock plan; board recommends approval.ACOGProxy Filing2 Dec 2025
- IPO funds will support the U.S. launch of an Alzheimer's drug, but financial risks remain high.ACOGRegistration Filing29 Nov 2025